TG Therapeutics Announces Publication in Blood Advances Describing Unique Immunomodulatory Effects on CLL T cells by Umbralisib
NEW YORK, July 08, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of preclinical data describing the unique immunomodulatory effects of umbralisib, the Company’s investigational oral once-daily dual inhibitor …